Dr. Eric Campeau serves as the Vice President, Translational Research at Thryv Therapeutics, researching how the development of SGK1 inhibitors represents a novel approach to target treatment resistant cancers, and complement existing therapies.

Eric has nearly 30 years of biomedical research experience, most recently as Vice President of Translational Biology at Zenith Epigenetics, Ltd. He has several publications in the field of epigenetics, cancer, DNA repair and metabolism. He has been involved in the preclinical and clinical development of ZEN-3694 since the beginning of Zenith in 2013. Most notably, the Translational Medicine team, led by Dr. Campeau, made key contributions in the design of a patient pre-selection approach for a randomized metastatic castration resistant prostate cancer study.

Prior to joining Zenith, Dr. Campeau joined Resverlogix Corp. in 2011 as a Scientist. He was previously an Instructor at the University of Massachusetts Medical School, and a Scientist at the Lawrence Berkeley National Laboratory.

Dr. Campeau obtained is Ph.D. degree in Human Genetics at McGill University.

• 

  Vice President, Translational Research in Thryv Therapeutics

  We will relentlessly pursue precision treatments targeting SGK1 to enable people to live their absolute best lives.Without Limits.